TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research In Vitro TMX-201 is more potent cytokine inducer than Imiquimod in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg . TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects . TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:TLR7